Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 2062317 | 2-Cyano-4-fluorobenzaldehyde | 77532-90-2 | 98% Min. | |
| 2062306 | 3-chloro-1-benzothiophene-2-carbonyl chloride | 21815-91-8 | 98% Min. | |
| 2062026 | 5-chloro-2,6-dimethoxy-4-methyl-8-nitroquinoline | 189746-21-2 | 96% Min. |  |
| 2062022 | 4-(3-Chloro-2-fluoroanilino)-6-hydroxy-7-methoxyquinazoline | 612501-52-7 | 96% Min. | -6-hydroxy-7-methoxyquinazoline_612501-52-7.png) |
| 2062014 | 2-chloro-6-methoxy-4-methylquinoline | 6340-55-2 | 96% Min. |  |
| 2061702 | CaCCinh-A01 | 407587-33-1 | 98% Min. |  |
| CaCCinh-A01, also known as TMEM16 Blocker I, is a TMEM16 Blocker. CaCCinh-A01 is a no | ||||
| 615201 | CLEFMA | 1246964-32-8 | 98% Min. |  |
| CLEFMA has anti-proliferative activity in H441 cells. CLEFMA may induce autophagic ce | ||||
| 2061307 | CMPD1 | 41179-33-3 | 98% Min. |  |
| CMPD1 is an inhibitor of MK2 activation, primarily inhibiting tubulin polymerisation | ||||
| 2061306 | CGP52411 | 145915-58-8 | 98% Min. |  |
| CGP52411, also known as DAPH, is a selective inhibitor of the epidermal growth factor | ||||
| 2051505 | CADD522 | 199735-88-1 | 98% Min. |  |
| CADD522 is a potent inhibitor of runt-related transcription factor-2 (RUNX2)-DNA bind | ||||
| S-204160 | 2-Chloro-7-fluoro-quinoline-3-carbaldehyde | 745830-16-4 | 98% Min. |  |
| S-203042 | cupreine | 524-63-0 | 98% Min. |  |
| 2041501 | CC-885 | 1010100-07-8 | 98% Min. |  |
| CC-885 is a potent Cereblon Modulator with potent antitumor activity mediated through | ||||
| 203071 | CC-90009 | 1860875-51-9 | 98% |  |
| CC-90009 is a modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubi | ||||
| 4281903 | 5-Chloro-2,6-Dimethoxy-4-Methylquinoline | 189746-19-8 | >96% |  |
| 5-Chloro-2,6-Dimethoxy-4-Methylquinoline, CAS 189746-19-8, is a key drug intermediate | ||||
| S510901 | Cenicriviroc Mesylate | 497223-28-6 | 98% Min. |  |
| Cenicriviroc (CVC) is an oral, once-daily, potent immunomodulator that blocks two che | ||||
| 193286 | CLP-290 | 1181083-81-7 | >98% |  |
| CLP-290 is a novel KCC2 modulator and prodrug of CLP-257, highly selective for KCC2 o | ||||
| 193283 | CT-1812 | 1802632-22-9 | >98% |  |
| CT-1812 is a first-in-class, orally available sigma-2/PGRMC1 antagonist (alpha beta o | ||||
| 193181 | Clofilium Tosylate | 92953-10-1 | >98% |  |
| Clofilium Tosylate is a K+ channel blocker, cardiac depressant, and anti-arrhythmic a | ||||
| 193124 | Cevipabulin fumarate | 849550-67-0 | >98% |  |
| Cevipabulin fumarate (TTI-237 fumarate) is an oral active, microtubule-active antitum | ||||
| 19342 | Conteltinib | 1384860-29-0 | >98% |  |
| Conteltinib is a tyrosine kinase inhibitor and an antineoplastic. | ||||
| 192274 | C25-140 | 1358099-18-9 | >98% |  |
| C25-140 is the first in class protein-protein interaction inhibitor of a RING-E3 liga | ||||
| 192192 | CCT-137690 | 1095382-05-0 | >98% |  |
| CCT137690, an aurora kinase inhibitor CCT137690, is a highly selective, orally bioava | ||||
| 191285 | CAY10602 | 374922-43-7 | >98% |  |
| CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening fo | ||||
| 19132 | Cilofexor ( GS-9674 ) | 1418274-28-8 | ≧98.0% |  |
| Cilofexor (also known as GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonis | ||||
| 1812283 | CCT241736 | 1402709-93-6 | >98% |  |
| CCT241736 is a potent and orally active and dual FLT3-Aurora inhibitor. | ||||
| 1811292 | CA-4948 | 1801343-74-7 | >98% |  |
| CA-4948 is a bioactive chemical. | ||||
| 1810291 | CCT129202 | 942947-93-5 | >98% |  |
| CCT129202 is an inhibitor of Aurora kinase activity and displays a favorable antineop | ||||
| 1810232 | CBM 301940 | 902146-11-6 | >98% |  |
| CBM 301940 is a potent malonyl-CoA decarboxylase inhibitor that is orally bioavailabl | ||||
| 1810225 | CID16020046 | 834903-43-4 | >98% |  |
| CID16020046 is a selective GPR55 inverse agonist. | ||||